|
1
|
Bonneau M, Bellesoeur A. [Adjuvant olaparib - High risk early breast cancer with BRCA1 or BRCA2 germline mutation]. Bull Cancer 2023; 110:1092-1093. [PMID: 37716861 DOI: 10.1016/j.bulcan.2023.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2023] [Revised: 07/02/2023] [Accepted: 07/09/2023] [Indexed: 09/18/2023]
Affiliation(s)
- Maëva Bonneau
- Institut universitaire du cancer de Toulouse, département d'oncologie médicale, Toulouse, France.
| | - Audrey Bellesoeur
- Institut Curie, département d'oncologie médicale, Paris, France; Institut Curie, département de radio-pharmacologie, Saint-Cloud, France
| |
Collapse
|
|
2
|
Salaün H, Saint-Ghislain M, Bellesoeur A, Beuzeboc P, Neuzillet C, Diéras V, Stern MH, Rodrigues M. [Homologous recombination deficiency and PARP inhibitors in therapeutics]. Bull Cancer 2021; 109:76-82. [PMID: 34799081 DOI: 10.1016/j.bulcan.2021.09.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2021] [Revised: 09/18/2021] [Accepted: 09/21/2021] [Indexed: 10/19/2022]
Abstract
PARP inhibitors are effective in different types of tumors such as ovarian, breast, prostate and pancreatic cancer. Many studies are in progress and may lead to prescription evolution. PARP inhibitors prescription is almost reserved to patients with a constitutional BRCA mutation or a somatic BRCA alteration or a tumor with a deficiency in homologous recombination. Nowadays, the diagnosis of homologous recombination deficit, HRD, is possible with the prescription of a myChoice CDx (Myriad) test. PARP inhibitors are studied in association with chemotherapy and targeted therapies but also with radiotherapy and with immune checkpoint inhibitors. Access to PARP inhibitors is challenged with the emergence of resistance mechanism. Various trials are now studying the possibility of reversing these resistance mechanisms.
Collapse
Affiliation(s)
- Hélène Salaün
- PSL research university, institut Curie, medical oncology department, 35, rue Dailly, 92210 Saint-Cloud, France
| | - Mathilde Saint-Ghislain
- PSL research university, institut Curie, medical oncology department, 26, rue d'Ulm, 75005 Paris, France
| | - Audrey Bellesoeur
- PSL research university, institut Curie, medical oncology department, 26, rue d'Ulm, 75005 Paris, France; PSL research university, institut Curie, radiopharmacology department, 35, rue Dailly, 92210 Saint-Cloud, France
| | - Philippe Beuzeboc
- Hôpital Foch, oncology and supportive care department, Suresnes, France
| | - Cindy Neuzillet
- PSL research university, institut Curie, medical oncology department, 35, rue Dailly, 92210 Saint-Cloud, France
| | - Véronique Diéras
- Centre Eugène-Marquis, medical oncology departement, Rennes, France
| | - Marc Henri Stern
- Institut Curie, INSERM U830 « cancer, heterogeneity, instability and plasticity », 26, rue d'Ulm, 75005 Paris, France
| | - Manuel Rodrigues
- PSL research university, institut Curie, medical oncology department, 26, rue d'Ulm, 75005 Paris, France; Institut Curie, INSERM U830 « cancer, heterogeneity, instability and plasticity », 26, rue d'Ulm, 75005 Paris, France.
| |
Collapse
|
|
3
|
Delaye M, Rodrigues M. [New drug approval: Olaparib and niraparib - first line in ovarian cancer]. Bull Cancer 2021; 108:350-351. [PMID: 33641880 DOI: 10.1016/j.bulcan.2021.01.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2020] [Accepted: 01/09/2021] [Indexed: 10/22/2022]
Affiliation(s)
- Matthieu Delaye
- Institut Curie, hôpital René-Huguenin, département d'oncologie médicale, 35, rue Dailly, 92210 Saint-Cloud, France; Association pour l'enseignement et la recherche des internes en oncologie (AERIO), 149, avenue du Maine, 75014 Paris, France
| | - Manuel Rodrigues
- Institut Curie, PSL research university, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France; Institut Curie, PSL research university, Inserm U830, 26, rue d'Ulm, 75005 Paris, France.
| |
Collapse
|